Related Experiment Video

Updated: Mar 21, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

900

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via

Xing-Ding Zhang1, Veerabhadran Baladandayuthapani2, Heather Lin2

  • 1Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu 215123, China; Xi'an Jiaotong University Suzhou Academy, Suzhou, Jiangsu 215123, China.

Cancer Cell
|May 3, 2016
PubMed

Insights

Tight junction protein 1 (TJP1) enhances sensitivity to proteasome inhibitors in multiple myeloma by suppressing specific signaling pathways. High TJP1 levels predict better patient response to bortezomib therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Proteasome inhibitors have improved multiple myeloma treatment outcomes.
  • Emerging primary and secondary resistance limit the efficacy of these therapies.
  • The precise determinants of plasma cell susceptibility to proteasome inhibitors remain incompletely understood.

Purpose of the Study:

  • To identify novel determinants of plasma cell proteasome inhibitor susceptibility.
  • To elucidate the molecular mechanisms underlying TJP1's role in proteasome inhibitor sensitivity.
  • To evaluate TJP1 as a potential predictive biomarker for proteasome inhibitor therapy in multiple myeloma.

Main Methods:

  • Investigated the role of TJP1 in modulating proteasome activity and drug sensitivity using in vitro and in vivo models.
  • Analyzed the signaling pathways (EGFR/JAK1/STAT3) regulated by TJP1.
  • Correlated TJP1 expression levels with clinical response to bortezomib in multiple myeloma patients.

Main Results:

  • TJP1 suppressed the expression of immunoproteasome subunits LMP7 and LMP2.
  • TJP1 decreased overall proteasome activity, enhancing sensitivity to proteasome inhibitors.
  • TJP1-mediated effects were linked to the suppression of EGFR/JAK1/STAT3 signaling.
  • High TJP1 expression in patient myeloma cells correlated with improved bortezomib response and duration.

Conclusions:

  • TJP1 acts as a key determinant of plasma cell susceptibility to proteasome inhibitors.
  • TJP1 influences proteasome activity and drug sensitivity via EGFR/JAK1/STAT3 signaling.
  • TJP1 is a promising predictive biomarker for identifying multiple myeloma patients likely to benefit from proteasome inhibitor therapy.

More Related Videos

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates09:47

Evaluation of Substrate Ubiquitylation by E3 Ubiquitin-ligase in Mammalian Cell Lysates

Published on: May 10, 2022

3.2K
In Vitro and In Vivo Approaches to Determine Intestinal Epithelial Cell Permeability10:22

In Vitro and In Vivo Approaches to Determine Intestinal Epithelial Cell Permeability

Published on: October 19, 2018

27.0K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K